[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344880-105":59,"doc-detail-344880-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","synergistic-gene-immunotherapy-for-lung-cancer-via-targeted-nanomedicine-restoring-genetic-tumor-suppression-and-activating-sting-pathway","Synergistic Gene Immunotherapy for Lung Cancer via Targeted Nanomedicine - Restoring Genetic Tumor Suppression and Activating STING Pathway","","Lung cancer, especially non-small cell lung cancer (NSCLC), remains difficult to treat because high mortality and complex pathogenesis limit the effectiveness of single-modality chemotherapy, immunotherapy, and gene therapy. A targeted gene-immunotherapeutic nanomedicine, pTMEM163/cGAMP@cRGD-BSA/LDHs (TGR-BLDHs), was engineered to deliver TMEM163, a NSCLC tumor suppressor gene, together with the cGAS/STING agonist cGAMP. TGR-BLDHs induced tumor-specific suppression and activated the cGAS/STING pathway in antigen-presenting and cancer cells, inhibiting tumor progression in vivo, demonstrating promising gene-immunotherapy potential with tumor specificity and biocompatibility.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/synergistic-gene-immunotherapy-for-lung-cancer-via-targeted-nanomedicine-restoring-genetic-tumor-suppression-and-activating-sting-pathway/344880/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/synergistic-gene-immunotherapy-for-lung-cancer-via-targeted-nanomedicine-restoring-genetic-tumor-suppression-and-activating-sting-pathway/344880.png","ImageObject",300,407,{"name":92,"@type":93},"Ava Thompson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What therapeutic problem does this study address in NSCLC?","Question",{"text":112,"@type":113},"NSCLC is difficult to control because single strategies such as chemotherapy or immunotherapy do not provide comprehensive inhibition, leaving resistance and recurrence issues. The study targets the need for more potent and precise approaches.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the nanomedicine TGR-BLDHs work?",{"text":117,"@type":113},"TGR-BLDHs delivers the TMEM163 tumor suppressor gene for targeted gene therapy and the cGAS/STING agonist cGAMP to activate the cGAS/STING pathway. This combination enables tumor-specific suppression and immune activation.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence is described for TMEM163 and its relevance?",{"text":121,"@type":113},"The text reports that TMEM163 is downregulated in NSCLC and associated with an optimistic prognosis, with supporting analyses across patient cohorts and cell/tissue comparisons. It also links TMEM163 expression to clinical survival correlations.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},344880,1790699160,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","This article is licensed under CC-BY 4.0   \n[www.acsnano.org](www.acsnano.org)  Article   \nSynergistic Gene Immunotherapy for Lung Cancer via Targeted Nanomedicine Restoring Genetic Tumor Suppression and Activating STING Pathway  \nWeiyu Chen,\\# Xinjie Zheng,\\# Yuan Wu, Yiming Xu, Hangqi Ni, Peng Xiao, Weibo Cai,* and Kai Wang*  \n Cite This: ACS Nano 2026, 20, 6138−6155  \nRead Online  \n\n|  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- |\n| ACCESS   | Metrics & More |  |  Article Recommendations |  | *sı Supporting Information |\n\nABSTRACT: Lung cancer, particularly non-small cell lung cancer (NSCLC), presents significant therapeutic challenges due to its high mortality and complex pathogenesis. General strategies, including chemotherapy, immunotherapy, and even novel gene therapy, fail to provide comprehensive inhibition against NSCLC individually. Here, a novel gene-immunotherapeutic nanomedicine, pTMEM163/cGAMP@cRGD-BSA/LDHs (TGR-BLDHs), was developed by employing cyclic Arg-Gly-Asp (cRGD)-modified bovine serum albumin/layered double hydroxide (BSA-LDH) nanoparticles for targeted delivery ofTMEM163, a newly identified tumor suppressor gene (TSG) of NSCLC and cGAS/STING agonist (cGAMP). TGR-BLDHs exhibited highly specific NSCLC tumor suppression via desirable tumor-targeted TSG gene therapy.  \nMeanwhile, TGR-BLDHs successfully evoked potent antitumor effects by activating the cGAS/STING pathway in both antigenpresenting and cancerous cells, eventually inhibiting tumor progression in vivo. The current study highlighted the potential of TGRBLDHs for effective gene immunotherapy against NSCLC with desirable tumor specificity and biocompatibility, offering a promising gene-immunotherapeutic strategy for NSCLC.  \nKEYWORDS: gene immunotherapy, tumor suppressor gene, STING agonist, layered double hydroxides, tumor-targeted delivery  \n■ INTRODUCTION  \nLung cancer remains one of the most common and deadly malignancies, continuing to be the leading cause of cancerrelated mortality worldwide, with the fastest-growing incidence and a dismal five-year survival rate of less than 20%.1,2 Nonsmall cell lung cancer (NSCLC) accounts for about 85% of lung cancer cases, including lung squamous cell carcinoma (LUSC), lung adenocarcinoma, and lung large cell carcinoma.3,4 According to lung cancer staging, treatments for NSCLC vary, ranging from surgery or chemotherapy to targeted therapy or immunotherapy.5 Despite the significant advancements in therapeutic strategies, issues such as drug resistance and postoperative recurrence persist.6,7 Particularly concerning are the significant side effects stemming from the shortage of drug specificity. There is a pressing need to develop more potent and precise therapeutic approaches.  \nOne promising strategy involves tumor suppressor genes (TSGs), which play a crucial role in limiting tumorigenesis and substantially influencing therapeutic outcomes.8 Typical TSGbased gene therapy has been evaluated in suppressing various tumor types, such as TP53 gene editing via a viral vector.9 Notably, the tissue-specific TSG would potentially enhance therapeutic outcomes compared to broad-spectrum TSG, particularly lowering off-target effects such as arresting the  \nnormal cell cycle via off-target TP53 overexpression. According to our bioinformatics analysis, transmembrane 163 (TMEM163), a zinc-binding protein, was identified, and its high expression in NSCLC was strongly associated with a lower risk of death (Figure 1A,B). Thus, it is vital to evaluate the role of TMEM163 in tumorigenesis and its potential as a TSG for NSCLC gene therapy.  \nMeanwhile, as an excellent TSG gene carrier, plasmid DNA (pDNA) has excellent stability and is easy to preserve.10 It is notable that incorporating a DNA targeting sequence (DTS), short conserved motifs recognized by specific transcription factors, could enhance the nucleus entry of pDNA.11 By employing DTS in TSG pDNA, such as the TMEM163 plasmid (pTMEM163), it would potentia","cbCaickZtm1QpuUM","https://ap.wps.com/l/cbCaickZtm1QpuUM","pdf",5963152,18,"English","# Abstract\n# Introduction\n## Tumor suppressor genes and NSCLC relevance\n## TMEM163 as a candidate tumor suppressor gene\n## Plasmid DNA targeting and delivery challenges","[{\"question\":\"What therapeutic problem does this study address in NSCLC?\",\"answer\":\"NSCLC is difficult to control because single strategies such as chemotherapy or immunotherapy do not provide comprehensive inhibition, leaving resistance and recurrence issues. The study targets the need for more potent and precise approaches.\"},{\"question\":\"How does the nanomedicine TGR-BLDHs work?\",\"answer\":\"TGR-BLDHs delivers the TMEM163 tumor suppressor gene for targeted gene therapy and the cGAS/STING agonist cGAMP to activate the cGAS/STING pathway. This combination enables tumor-specific suppression and immune activation.\"},{\"question\":\"What evidence is described for TMEM163 and its relevance?\",\"answer\":\"The text reports that TMEM163 is downregulated in NSCLC and associated with an optimistic prognosis, with supporting analyses across patient cohorts and cell/tissue comparisons. It also links TMEM163 expression to clinical survival correlations.\"}]","Synergistic Gene Immunotherapy for Lung Cancer via Targeted Nanomedicine - Restoring Genetic Tumor Suppression and Activating STING Pathway | PDF",1790055533,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/24582016e608221e4be0fb8096750145.webp",983,1296,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d9c87eeec0195f3fae90017e11274950.webp",982,1295,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/95d77b0f0d13477dfef38e312b2ed8fe.webp",981,1293,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/15eb4172aec95c1d5d126a97cf6df500.webp",980,1292]